Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

233 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: the Euroinject One trial.
Kastrup J, Jørgensen E, Rück A, Tägil K, Glogar D, Ruzyllo W, Bøtker HE, Dudek D, Drvota V, Hesse B, Thuesen L, Blomberg P, Gyöngyösi M, Sylvén C; Euroinject One Group. Kastrup J, et al. Among authors: gyongyosi m. J Am Coll Cardiol. 2005 Apr 5;45(7):982-8. doi: 10.1016/j.jacc.2004.12.068. J Am Coll Cardiol. 2005. PMID: 15808751 Free article. Clinical Trial.
Evaluation of myocardial perfusion and left ventricular function six months after percutaneous transmyocardial laser revascularization: comparison of two Ho-YAG laser systems with the same wavelength, but different energy delivery and navigation systems.
Strehblow C, Gyöngyösi M, Khorsand A, Sperker W, Gatterer M, Graf S, Sochor H, Glogar D. Strehblow C, et al. Among authors: gyongyosi m. Lasers Surg Med. 2003;33(5):273-81. doi: 10.1002/lsm.10230. Lasers Surg Med. 2003. PMID: 14677154
NOGA-guided analysis of regional myocardial perfusion abnormalities treated with intramyocardial injections of plasmid encoding vascular endothelial growth factor A-165 in patients with chronic myocardial ischemia: subanalysis of the EUROINJECT-ONE multicenter double-blind randomized study.
Gyöngyösi M, Khorsand A, Zamini S, Sperker W, Strehblow C, Kastrup J, Jorgensen E, Hesse B, Tägil K, Bøtker HE, Ruzyllo W, Teresiñska A, Dudek D, Hubalewska A, Rück A, Nielsen SS, Graf S, Mundigler G, Novak J, Sochor H, Maurer G, Glogar D, Sylven C. Gyöngyösi M, et al. Circulation. 2005 Aug 30;112(9 Suppl):I157-65. doi: 10.1161/01.CIRCULATIONAHA.105.525782. Circulation. 2005. PMID: 16159809 Clinical Trial.
Design and rationale for the Myocardial Stem Cell Administration After Acute Myocardial Infarction (MYSTAR) Study: a multicenter, prospective, randomized, single-blind trial comparing early and late intracoronary or combined (percutaneous intramyocardial and intracoronary) administration of nonselected autologous bone marrow cells to patients after acute myocardial infarction.
Nyolczas N, Gyöngyösi M, Beran G, Dettke M, Graf S, Sochor H, Christ G, Edes I, Balogh L, Krause KT, Jaquet K, Kuck KH, Benedek I, Hintea T, Kiss R, Préda I, Kotevski V, Pejkov H, Dudek D, Heba G, Sylven C, Charwat S, Jacob R, Maurer G, Lang I, Glogar D. Nyolczas N, et al. Among authors: gyongyosi m. Am Heart J. 2007 Feb;153(2):212.e1-7. doi: 10.1016/j.ahj.2006.10.027. Am Heart J. 2007. PMID: 17239678 Clinical Trial.
Combined delivery approach of bone marrow mononuclear stem cells early and late after myocardial infarction: the MYSTAR prospective, randomized study.
Gyöngyösi M, Lang I, Dettke M, Beran G, Graf S, Sochor H, Nyolczas N, Charwat S, Hemetsberger R, Christ G, Edes I, Balogh L, Krause KT, Jaquet K, Kuck KH, Benedek I, Hintea T, Kiss R, Préda I, Kotevski V, Pejkov H, Zamini S, Khorsand A, Sodeck G, Kaider A, Maurer G, Glogar D. Gyöngyösi M, et al. Nat Clin Pract Cardiovasc Med. 2009 Jan;6(1):70-81. doi: 10.1038/ncpcardio1388. Epub 2008 Nov 11. Nat Clin Pract Cardiovasc Med. 2009. PMID: 19002124 Clinical Trial.
A randomised, double-blind, placebo-controlled, multicentre study of the safety and efficacy of BIOBYPASS (AdGVVEGF121.10NH) gene therapy in patients with refractory advanced coronary artery disease: the NOVA trial.
Kastrup J, Jørgensen E, Fuchs S, Nikol S, Bøtker HE, Gyöngyösi M, Glogar D, Kornowski R. Kastrup J, et al. Among authors: gyongyosi m. EuroIntervention. 2011 Feb;6(7):813-8. doi: 10.4244/EIJV6I7A140. EuroIntervention. 2011. PMID: 21252014 Clinical Trial.
233 results